Usa India covid-19 patient Usa India

Natco Pharma seeks approval for Covid drug candidate Molnupiravir

Reading now: 511
www.livemint.com

clinical trial of Molnupiravir Capsules, to be used for the treatment of Covid-19 positive patients.The capsule has been developed by American pharma major Merck along with Ridgeback Biotherapeutics.According to a press release from Natco, pre-clinical data have shown that Molnupiravir has broad anti-influenza activity, including highly potent inhibition of SARS-CoV-2 replication."Patients treated with Molnupiravir achieved response within 5 days of therapy indicating that the duration of treatment with Molnupiravir is short, with the additional advantage of being an oral therapy," it said.Natco is hoping that CDSCO would give emergency approval of this drug based on "compassionate use" for patients."Compassionate use" approval is given for.

Read more on livemint.com
The website covid-19.rehab is an aggregator of news from open sources. The source is indicated at the beginning and at the end of the announcement. You can send a complaint on the news if you find it unreliable.

Related News

DMCA